|
1
|
Bartella I and Dufour JF: Clinical
diagnosis and staging of intrahepatic cholangiocarcinoma. J
Gastrointestin Liver Dis. 24:481–489. 2015.PubMed/NCBI
|
|
2
|
Guo LH and Xu HX: Contrast-enhanced
ultrasound in the diagnosis of hepatocellular carcinoma and
intrahepatic cholangiocarcinoma: Controversy over the ASSLD
Guideline. Biomed Res Int. 2015:3491722015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guro H, Kim JW, Choi Y, Cho JY, Yoon YS
and Han HS: Multidisciplinary management of intrahepatic
cholangiocarcinoma: Current approaches. Surg Oncol. 26:146–152.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoh T, Hatano E, Nishio T, Seo S, Taura K,
Yasuchika K, Okajima H, Kaido T and Uemoto S: Significant
improvement in outcomes of patients with intrahepatic
cholangiocarcinoma after surgery. World J Surg. 40:2229–2236. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guglielmi A, Ruzzenente A, Campagnaro T,
Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G and
Iacono C: Intrahepatic cholangiocarcinoma: Prognostic factors after
surgical resection. World J Surg. 33:1247–1254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu D, Shi X, Meng G, Chen J, Yan C, Jiang
Y, Wei J and Ding Y: Kidney-type glutaminase (GLS1) is a biomarker
for pathologic diagnosis and prognosis of hepatocellular carcinoma.
Oncotarget. 6:7619–7631. 2015.PubMed/NCBI
|
|
8
|
Qie S, Chu C, Li W, Wang C and Sang N:
ErbB2 activation upregulates glutaminase 1 expression which
promotes breast cancer cell proliferation. J Cell Biochem.
115:498–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang F, Zhang Q, Ma H, Lv Q and Zhang T:
Expression of glutaminase is upregulated in colorectal cancer and
of clinical significance. Int J Clin Exp Pathol. 7:1093–1100.
2014.PubMed/NCBI
|
|
10
|
Huang F, Wang BR and Wang YG: Role of
autophagy in tumorigenesis, metastasis, targeted therapy and drug
resistance of hepatocellular carcinoma. World J Gastroenterol.
24:4643–4651. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klymkowsky MW: Beta-catenin and its
regulatory network. Hum Pathol. 36:225–227. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee SY, Jeon HM, Ju MK, Jeong EK, Kim CH,
Park HG, Han SI and Kang HS: Dlx-2 and glutaminase upregulate
epithelial-mesenchymal transition and glycolytic switch.
Oncotarget. 7:7925–7939. 2016.PubMed/NCBI
|
|
13
|
Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan
CJ, Shi YH, Huang C, Wang Z, He YF and Fan J: Capn4 overexpression
underlies tumor invasion and metastasis after liver transplantation
for hepatocellular carcinoma. Hepatology. 49:460–470. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo
J, Ni Z, Zhang M, Kong X, Hoffman LL, et al: An integrated
transcriptomic and computational analysis for biomarker
identification in gastric cancer. Nucleic Acids Res. 39:1197–1207.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Skrzypczak M, Goryca K, Rubel T, Paziewska
A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J:
Modeling oncogenic signaling in colon tumors by multidirectional
analyses of microarray data directed for maximization of analytical
reliability. PLoS One. 5(pii): e130912010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abu Aboud O, Habib SL, Trott J, Stewart B,
Liang S, Chaudhari AJ, Sutcliffe J and Weiss RH: Glutamine
addiction in kidney cancer suppresses oxidative stress and can Be
exploited for real-time imaging. Cancer Res. 77:6746–6758. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan T, Gao L, Wu G, Shen G, Xie S, Wen H,
Yang J, Zhou Y, Tu Z and Qian W: Elevated expression of glutaminase
confers glucose utilization via glutaminolysis in prostate cancer.
Biochem Biophys Res Commun. 456:452–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qureshi R, Arora H and Rizvi MA: EMT in
cervical cancer: Its role in tumour progression and response to
therapy. Cancer Lett. 356:321–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Terry S, Savagner P, Ortiz-Cuaran S,
Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into
the role of EMT in tumor immune escape. Mol Oncol. 11:824–846.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ulanet DB, Couto K, Jha A, Choe S, Wang A,
Woo HK, Steadman M, DeLaBarre B, Gross S, Driggers E, et al:
Mesenchymal phenotype predisposes lung cancer cells to impaired
proliferation and redox stress in response to glutaminase
inhibition. PLoS One. 9:e1151442014. View Article : Google Scholar : PubMed/NCBI
|
